TRYbeCA-1
Eryaspase, an enzyme carried inside red blood cells, did not lengthen survival when added to second-line chemotherapy for pancreatic cancer.
Overview
TRYbeCA-1 randomised patients with metastatic pancreatic adenocarcinoma progressing after first-line treatment to eryaspase plus gemcitabine and nab-paclitaxel or irinotecan-based chemotherapy, or chemotherapy alone. The primary endpoint of overall survival was not met when the trial reported in 2021.
Similar pages
not linked directly; found by shared links- CompanyPhaxiam Therapeutics (formerly ERYtech Pharma)
- TrialStudy to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Adv
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialSaltikva for Metastatic Pancreatic Cancer
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialActuate 1801 Part 3B (elraglusib)
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialLAPIS
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialPANOVA-3
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialNAPOLI 3
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- Key paperMPACT (Von Hoff 2013): nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.